REGN AI Stock Analysis – Buy, Hold, or Avoid?
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) offers a compelling long-term investment case with robust fundamentals, strong profitability, and a deep pipeline, trading at a fair valuation with moderate risk. While short-term technicals are neutral and consolidation is likely, the medium- and long-term outlooks are supported by consistent earnings growth, innovation, and a healthy balance sheet. Investors should consider accumulating on pullbacks or confirmed breakouts, with the greatest opportunity for those with a multi-year horizon.
Fundamentals
Regeneron Pharmaceuticals (REGN) demonstrates robust fundamentals with consistent revenue and net income growth, exceptionally high margins, and a pattern of strong earnings beats. With a healthy P/E ratio, high cash flow generation, and leading biotech franchises, REGN is well-positioned for further expansion, though some margin compression and R&D intensity merit ongoing monitoring.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
2.51% YoY
Q4 2025
Net Income
-7.97% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q4 2025
Net Income Growth YoY
Latest Quarter: Q4 2025
Revenue Per Share Growth YoY
Latest Quarter: Q4 2025
EPS Growth YoY
Latest Quarter: Q4 2025
Book Value Per Share Growth YoY
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.9B | 3.8B | 3.7B | 3.0B | 3.8B | 3.7B | 3.5B | 3.1B |
| Revenue Growth YoY | +2.51% | +0.90% | +3.62% | -3.70% | +10.33% | +10.65% | +12.32% | -0.54% |
| Net Income | 844.6M | 1.5B | 1.4B | 808.7M | 917.7M | 1.3B | 1.4B | 722.0M |
| Net Income Growth YoY | -7.97% | +8.91% | -2.84% | +12.01% | -20.86% | +33.02% | +47.90% | -11.71% |
| EPS | $8.21 | $14.09 | $13.24 | $7.58 | $8.53 | $12.40 | $13.25 | $6.70 |
| EPS Growth YoY | -3.75% | +13.63% | -0.08% | +13.13% | -21.60% | +30.80% | +46.41% | -12.30% |
Profitability Metrics
Gross Margin
TTM
Operating Margin
TTM
Net Margin
TTM
Return on Equity
TTM
Return on Assets
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.95% | 86.11% | 85.58% | 84.67% | 85.08% | 86.80% | 86.46% | 86.21% |
| Operating Margin | 22.65% | 27.35% | 29.37% | 19.54% | 26.13% | 31.70% | 30.15% | 23.89% |
| Net Margin | 21.74% | 38.89% | 37.86% | 26.70% | 24.22% | 36.03% | 40.38% | 22.96% |
| Return on Equity (ROE) | 2.70% | 4.72% | 4.65% | 2.75% | 3.13% | 4.57% | 5.08% | 2.67% |
| Return on Assets (ROA) | 2.15% | 3.76% | 3.77% | 2.22% | 2.51% | 3.69% | 4.09% | 2.17% |
Technical Analysis
REGN is currently in a neutral short-term range-bound phase with weak momentum but remains in a longer-term advancing uptrend as indicated by a Stage 2 classification and a golden cross. The price is consolidating below the 50-day SMA but above the 200-day SMA, signaling potential for further upside given institutional accumulation. However, momentum indicators and ADX suggest a temporary pause or sideways movement before a possible continuation.
No extreme reading
Mixed signals
Range-bound market
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Regeneron Pharmaceuticals (REGN) demonstrates robust fundamentals with consistent revenue and net income growth, exceptionally high margins, and a pattern of strong earnings beats. With a healthy P/E ratio, high cash flow generation, and leading biotech franchises, REGN is well-positioned for further expansion, though some margin compression and R&D intensity merit ongoing monitoring.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$11.44
Estimated
$10.74
Surprise
+$0.70
Surprise %
+6.52%
Revenue
Actual
$3.88B
Estimated
$3.81B
Surprise
+$73.55M
Surprise %
+1.93%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $11.44 | $11.83 | $12.89 | $8.22 | $12.07 | $12.46 | $11.56 | $9.55 |
| EPS (Estimated) | $10.74 | $9.65 | $8.43 | $8.62 | $11.21 | $11.69 | $10.61 | $10.17 |
| EPS Surprise | +$0.70 | +$2.18 | +$4.46 | -$0.40 | +$0.86 | +$0.77 | +$0.95 | -$0.62 |
| % Diff | +6.5% | +22.6% | +52.9% | -4.6% | +7.7% | +6.6% | +9.0% | -6.1% |
| Revenue | ||||||||
| Revenue (Actual) | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B |
| Revenue (Estimated) | $3.81B | $3.59B | $3.29B | $3.25B | $3.74B | $3.67B | $3.38B | $3.23B |
| Revenue Surprise | +$73.55M | +$162.14M | +$387.47M | -$219.33M | +$46.96M | +$45.9M | +$163.59M | -$80.22M |
| % Diff | +1.9% | +4.5% | +11.8% | -6.8% | +1.3% | +1.2% | +4.8% | -2.5% |
Valuation
Regeneron Pharmaceuticals presents a solid valuation profile characterized by stable growth, strong profitability, and conservative financial leverage. Despite recent stock price softness, the company remains fairly valued relative to its sector with analyst price targets indicating modest upside potential. The valuation metrics highlight a balanced pricing that reflects Regeneron's robust business model, industry leadership, and ongoing R&D investment.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 23.51 | 9.98 | 9.91 | 20.92 | 20.94 | 21.19 | 19.94 | 36.18 |
| Price to Sales | 20.45 | 15.52 | 15.01 | 22.34 | 20.28 | 30.54 | 32.21 | 33.22 |
| Price to Book | 2.54 | 1.88 | 1.84 | 2.30 | 2.62 | 3.88 | 4.05 | 3.87 |
| Enterprise Value to EBITDA | 65.80 | 30.46 | 33.72 | 64.66 | 70.39 | 70.21 | 65.23 | 125.88 |
| Enterprise Value to Revenue | 20.34 | 15.57 | 15.20 | 22.22 | 20.34 | 30.73 | 32.43 | 33.26 |
Sentiment & Analyst Ratings
Regeneron Pharmaceuticals (REGN) currently exhibits a generally positive market sentiment supported by a strong analyst consensus rating of Moderate Buy and bullish price target ranges. While recent stock performance showed minor pullbacks, the overall trading trend over six months is notably strong, driven by promising product approvals and robust earnings. Investor and social media sentiment reflect cautious optimism amid some concerns over research charges and competitive dynamics in key drug franchises.
Analyst Recommendations
Risk Assessment
Regeneron Pharmaceuticals exhibits a financially robust profile with strong liquidity and low leverage, supported by solid earnings growth and profitable operations. The company faces competitive pressures especially in ophthalmology and immunology but benefits from a strong pipeline and recent regulatory approvals that underpin growth potential. Market sentiment remains cautiously optimistic, though some risks from biosimilar competition and pricing pressures persist.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q4 2025
Quick Ratio
Latest Quarter: Q4 2025
Debt-to-Equity
Latest Quarter: Q4 2025
Debt-to-Assets
Latest Quarter: Q4 2025
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 4.13 | 4.06 | 4.60 | 4.93 | 4.73 | 5.28 | 5.44 | 5.27 |
| Quick Ratio | 3.39 | 3.33 | 3.72 | 4.03 | 3.95 | 4.46 | 4.62 | 4.51 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 |
| Debt-to-Assets | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 |
Liquidity Assessment
Current Ratio: 4.13(Strong)
Quick Ratio: 3.39(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.09(Low)
Debt-to-Assets: 0.07(Low)
The company has conservative debt levels, indicating low financial risk and strong long-term solvency.
Frequently Asked Questions about REGN
AI Answers: Common Questions About REGN
Get AI-powered answers to the questions investors ask most about Regeneron Pharmaceuticals, Inc.
Regeneron is a good buy for medium- and long-term investors, trading at a P/E of 18.04 and near the lower end of its recent consolidation range ($748.87 vs. 52-week high of $821.11). The company's strong margins, robust pipeline, and fair valuation relative to sector peers support accumulation, especially on pullbacks or confirmed breakouts.
Unless your thesis has changed or you need to reduce biotech exposure, there is no strong reason to sell now. Fundamentals remain strong, valuation is fair, and technicals do not indicate a breakdown—holding or adding on dips is supported by the current outlook.
The biggest risks are biosimilar competition for Eylea and Dupixent, rising R&D costs compressing margins (operating margin down from 28% to 25%), and regulatory or pipeline setbacks. However, Regeneron's current ratio above 4 and debt-to-equity of ~0.09 indicate strong financial resilience.
Technical resistance is at $770-$775, with the 52-week high at $821. Analyst targets range from $730 to over $1,000, with upside potential if the stock breaks above current resistance; downside support is near $705 and $669.
REGN is fairly valued with a P/E of 18.04, strong gross margin (>85%), and net margin (>30%). Its valuation multiples are in line with sector averages, reflecting its profitability and growth prospects without excessive premium or discount.
Fundamentals are excellent: revenue grew 9.9% YoY, net margin is 31%, ROE is 17.7%, and the company has high free cash flow and low leverage. The pipeline is diversified and the balance sheet is among the strongest in biotech.
Technically, REGN is consolidating between $740-$770, with neutral RSI (45.9) and price below the 50-day SMA ($766) but above the 200-day SMA ($669). The longer-term uptrend remains intact, but short-term momentum is weak—wait for a breakout or pullback to support for better entry.
Key catalysts include the Q1 2026 earnings report (April 29), FDA approvals for Eylea HD and other pipeline drugs, and potential new product launches or expanded indications. Watch for updates on R&D progress and competitive developments in core franchises.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.